Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Supervisory Board
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Innate Immunity & NK cells
    • Antibody formats
    • ANKET®: Our NK cell engager Platform
    • Publications
  • Products
    • Pipeline overview
    • Clinical trials
    • ------------------
    • Lacutamab
    • Monalizumab
    • IPH5201
    • IPH5301
    • IPH6101
    • IPH62
    • IPH6401
    • IPH6501
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
    • Financial and Regulatory Information
    • General Shareholders Meeting
    • Governance
    • Resources
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

Q3 2024 Financial Results and Business Update | November 13, 2024


Press Release and webcast

ANKET® | Antibody-based NK cell Engager Therapeutics


Discover our proprietary platform

Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma


More about our lead asset

Harnessing the power of NK cells to develop therapeutic antibodies


Discover our cutting-edge science

Collaborating with a strong network to advance our pipeline


Discover our partnering opportunities

Previous Next

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

See company profile

Latest news

Innate Pharma releases its 2025 financial calendar

November 20, 2024

Innate Pharma announces publication in Science Immunology highlighting innovative next-generation ANKET® IPH6501

November 19, 2024

Innate Pharma reports Third Quarter 2024 Business Update and Financial Results

November 13, 2024
See all press releases

Footer

  • Contact
  • Location
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

 +33 (0)4 30 30 30 30

 Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Supervisory Board
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Innate Immunity & NK cells
    • Antibody formats
    • ANKET®: Our NK cell engager Platform
    • Publications
  • Products
    • Pipeline overview
    • Clinical trials
    • ------------------
    • Lacutamab
    • Monalizumab
    • IPH5201
    • IPH5301
    • IPH6101
    • IPH62
    • IPH6401
    • IPH6501
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
    • Financial and Regulatory Information
    • General Shareholders Meeting
    • Governance
    • Resources
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers